Caraco's Detroit plant rehab timeline extended

Caraco says it's unlikely to resume manufacturing at its Detroit facility before April, as it had estimated earlier. Following a review with its GMP consultants on the remediation steps completed since it entered into a consent decree with the FDA in September 2009, and those still pending, the generics maker has revised its restart estimate. Remediation continues, the company says, but it can't predict when manufacturing and distribution operations will resume. Caraco release  

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.